NCT02559024View on ClinicalTrials.gov

Anti-OX40 Antibody (MEDI6469) in Patients With Metastatic Colorectal Cancer

PHASE1TerminatedINTERVENTIONAL

Enrollment

4

Participants

Timeline

Start Date

March 14, 2016

Primary Completion Date

October 31, 2018

Study Completion Date

October 31, 2018

Conditions

Colorectal Neoplasms

Interventions

DRUG

MEDI6469

MEDI6469 0.4 mg/kg IV x 3 doses over 5-6 days

Trial Locations (1)

97213

Portland Providence Medical Center, Portland

Sponsors

Collaborators (1)

All Listed Sponsors

collaborator

MedImmune LLC

INDUSTRY

lead

Providence Health & Services

OTHER